Drug Trial Radar · NCT06984926
A Study to Test How Well Multiple Doses of BI 3810477 Are Tolerated by Healthy Adults
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Jun 6, 2025
Primary completion
Mar 9, 2026
Study completion Mar 9, 2026
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- May 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 3810477 in healthy male and female trial participants when given as multiple rising doses.
Conditions
- Healthy
Interventions
BI 3810477Drug
BI 3810477
PlaceboDrug
Placebo for BI 3810477
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of any treatment-emergent adverse events assessed as drug-related by the investigatorTime frame: Up to Day 117
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SGS Life Science Services - Clinical Research
Edegem, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.